Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03327857 · ClinicalTrials.gov registry record · Phase 1
Neihulizumab (ALTB-168) in Patients With Steroid-refractory Acute Graft-versus-host Disease or Treatment-refractory Acute Graft-versus-host Disease
A Phase 1 study, sponsored by AltruBio.
- Completed
- Registry status
- Phase 1
- Development phase
- 37
- Enrollment target
NCT03327857 is a Phase 1 study that has completed, run by AltruBio. The registered enrollment target is 37 participants.
The verdict
NCT03327857, a Phase 1 study, has completed, sponsored by AltruBio.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 37 participants
- Enrollment target
Study Summary
A Phase I study to establish the pharmacokinetics, pharmacodynamics, safety and efficacy profiles of Neihulizumab in patients with steroid-refractory or treatment refractory acute graft-versus-host disease (SR/TR-aGVHD)
Interventions
- BIOLOGICAL Neihulizumab (ALTB-168)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2018-05-31 |
| Est. Completion | 2022-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03327857
The ClinicalTrials.gov registry entry for NCT03327857 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AltruBio, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Neihulizumab (ALTB-168) is the first listed.
NCT03327857 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03327857 about?
NCT03327857 is a clinical study titled "Neihulizumab (ALTB-168) in Patients With Steroid-refractory Acute Graft-versus-host Disease or Treatment-refractory Acute Graft-versus-host Disease". A Phase I study to establish the pharmacokinetics, pharmacodynamics, safety and efficacy profiles of Neihulizumab in patients with steroid-refractory or treatment refractory acute graft-versus-host disease (SR/TR-aGVHD)
What is the current status of trial NCT03327857?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 37 participants. The study started on 2018-05-31. Estimated completion is 2022-12-31.
What interventions are being tested in trial NCT03327857?
The interventions under investigation include: Neihulizumab (ALTB-168) (BIOLOGICAL).
Who is sponsoring clinical trial NCT03327857?
This trial is sponsored by AltruBio, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.